Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.43 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30359 | 0.88 | AKR1B1 (0.76) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| SCHEMBL29410826 | 0.88 | AKR1B1 (0.76) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| Hydrochloric Acid SCHEMBL9621764 | 0.85 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| Hydrochloric Acid SCHEMBL6767821 | 0.85 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| Hydrogen Sulfide SCHEMBL27426416 | 0.85 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| SCHEMBL28842838 | 0.85 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| Iodide SCHEMBL31305035 | 0.85 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| SCHEMBL9336233 | 0.85 | AKR1B1 (0.55) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| Methyl Alcohol SCHEMBL28299530 | 0.83 | AKR1B1 (0.70) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| SCHEMBL4086192 | 0.83 | AKR1B1 (0.57) | AKR1B1TDP1BCAT2CXCL8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303512-B1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | EP | claimed |
| JP-2004505079-A | — | — | 2004-02-19 | — | — | JP | claimed |
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2003-11-20 | — | — | US | claimed |
| US-6613911-B2 | Reaction of haloarylacetic acids or esters with olefins to give vinylarylacetic acids or esters, oxidation with an oxidizing reagent gives formylarylacetic acids or esters | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | claimed |
| EP-1303512-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | claimed |
| WO-2003011917-A1 | METHOD OF CURING ELASTOMERS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2002-06-13 | — | — | US | claimed |
| WO-2002010161-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | claimed |
| EP-0906265-B1 | CHEMICAL PROCESS | SYNGENTA LTD (GB) | 2001-08-29 | — | — | EP | claimed |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | BRISTOL-MYERS SQUIBB COMPANY | 2001-06-21 | — | — | US | claimed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-117946058-A | Preparation method of 3-isochromone | 上海试四化学品有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024040169-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2024-02-22 | — | — | WO | disclosed |
| CN-115417849-B | Method for catalytic synthesis of 3-isochromone | 河南省化工研究所有限责任公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-115894447-A | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-4045438-A | Cephalosporin antibiotics | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1977-08-30 | — | — | US | disclosed |
| US-4031083-A | Cephalosporin antibiotics | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1977-06-21 | — | — | US | disclosed |
| US-4026887-A | Cephalosporin antibiotics | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1977-05-31 | — | — | US | disclosed |
| US-3994875-A | CEPHALOSPORINS, PENICILLINS | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1976-11-30 | — | — | US | disclosed |
| US-3948904-A | ANTIBIOTICS | YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNT1, CCNA1 | AKR1B1 684/4885TDP1 3065/4885BCAT2 125/4885 |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CCNT1, CCNI, CCNA1 | AKR1B1 563/4885TDP1 3314/4885BCAT2 132/4885 |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNA1, CCNT1 | AKR1B1 719/4885TDP1 3170/4885BCAT2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.